While scientists&nbsp;are continuing to study chloroquine and hydroxychloroquine as&nbsp;potential cure the coronavirus pandemic,&nbsp;concerns are being&nbsp;raised&nbsp;about the efficacy and safety of the drugs.

In&nbsp;a preliminary study in Brazil it has been&nbsp;discovered that&nbsp;a high dose of chloroquine diphosophate is&nbsp;associated with a severe type of arrhythmia, or irregular heartbeat.

Also read:&nbsp;<a href="https://www.wionews.com/world/imf-approves-debt-relief-for-25-poor-countries-to-help-them-address-coronavirus-pandemic-292341">IMF approves debt relief for 25 poor countries to help fight Covid-19</a>

The study was shut down after it was unable to treat patients infected with the novel virus.

Hospitals in Sweden have also received guidance directing clinicians not to use chloroquine to treat Covid-19 patients outside of clinical trials.

Also read:&nbsp;<a href="https://www.wionews.com/world/coronavirus-is-10-times-deadlier-than-swine-flu-who-292313" hreflang="en">Coronavirus is 10 times deadlier than swine flu: WHO</a>

The guidance states that "considering the very low evidence of any significant effect on Covid-19 and since serious side effects can't be ruled out, the use of chloroquine outside of clinical trials is not recommended."

Magnus Gisslén, professor and senior doctor at the Sahlgrenska University Hospital in Gothenburg, Sweden along with his&nbsp;team&nbsp;have seen "a serious effect on the heart" linked to using the medication, he said.

He added that patients with lower kidney function also had a difficult time taking the drug.

Last week, the American Heart Association, the American College of Cardiology and the Heart Rhythm Society&nbsp;issued guidance&nbsp;about critical cardiovascular considerations for the use of hydroxychloroquine and azithromycin to treat the novel coronavirus, saying doctors must consider "potential serious implications for people with existing cardiovascular disease."

World Health Organization officials on Monday said they "eagerly await" the outcomes of studies evaluating the use of chloroquine and hydroxychloroquine as possible Covid-19 treatment options, especially as the drugs already are being used "off label" to treat some patients in certain countries.

While scientists are continuing to study chloroquine and hydroxychloroquine as potential cure the coronavirus pandemic, concerns are being raised about the efficacy and safety of the drugs.

While scientists are continuing to study chloroquine and hydroxychloroquine as potential cure the coronavirus pandemic, concerns are being raised about the efficacy and safety of the drugs. In a preliminary study in Brazil it has been discovered that a high dose of chloroquine diphosophate is associated with a severe type of arrhythmia, or irregular heartbeat. Also read: IMF approves debt relief for 25 poor countries to help fight Covid-19 The study was shut down after it was unable to treat patients infected with the novel virus. Hospitals in Sweden have also received guidance directing clinicians not to use chloroquine to treat Covid-19 patients outside of clinical trials. Also read: Coronavirus is 10 times deadlier than swine flu: WHO The guidance states that "considering the very low evidence of any significant effect on Covid-19 and since serious side effects can't be ruled out, the use of chloroquine outside of clinical trials is not recommended." Magnus Gisslén, professor and senior doctor at the Sahlgrenska University Hospital in Gothenburg, Sweden along with his team have seen "a serious effect on the heart" linked to using the medication, he said. He added that patients with lower kidney function also had a difficult time taking the drug. Last week, the American Heart Association, the American College of Cardiology and the Heart Rhythm Society issued guidance about critical cardiovascular considerations for the use of hydroxychloroquine and azithromycin to treat the novel coronavirus, saying doctors must consider "potential serious implications for people with existing cardiovascular disease." World Health Organization officials on Monday said they "eagerly await" the outcomes of studies evaluating the use of chloroquine and hydroxychloroquine as possible Covid-19 treatment options, especially as the drugs already are being used "off label" to treat some patients in certain countries.

COVID-19 treatment: Chloroquine and hydroxychloroquine can cause heart problems

All India Institute Of Medical Sciences (AIIMS) Medical Superintendent has issued an order to those doctors/paramedics/nurses involved in the treatment of COVID-19 patients can get hydroxychloroquine tablets from their respective departments.

The order comes hours after the Ministry of External Affairs informed that the government decided to licence paracetamol and hydroxychloroquine in appropriate quantities to all the neighbouring countries, dependent on the country's capabilities.&nbsp;

Meanwhile, AIIMS today informed that it would provide five N95 masks to each medical personnel for 20 days.

Only five N95 masks will be provided to each doctor, nursing officer, technical staff, security guard and maintenance staff for 20 days at the AIIMS.

&nbsp;"N95 masks to be disinfected by individual users and re-used at least four times each, whereby these will suffice for about 20 days" the circular issued by AIIMS read.

Earlier on Saturday, AIIMS New Delhi administration had said that there is no shortage of Personnel Protective Equipment (PPE) for the healthcare workers at the institute.

"AIIMS administration reiterates that there is no shortage of PPEs for health care workers (HCW) at the Institute" read the statement from Medial and Protocol Division, AIIMS, New Delhi.

Personnel Protective Equipment acts as the first line of defence for the medical personnel treating COVID-19 positive patients.

All India Institute Of Medical Sciences (AIIMS) Medical Superintendent has issued an order to those doctors/paramedics/nurses involved in the treatment of COVID-19 patients can get hydroxychloroquine tablets from their respective departments.

All India Institute Of Medical Sciences (AIIMS) Medical Superintendent has issued an order to those doctors/paramedics/nurses involved in the treatment of COVID-19 patients can get hydroxychloroquine tablets from their respective departments. The order comes hours after the Ministry of External Affairs informed that the government decided to licence paracetamol and hydroxychloroquine in appropriate quantities to all the neighbouring countries, dependent on the country's capabilities. Meanwhile, AIIMS today informed that it would provide five N95 masks to each medical personnel for 20 days. Only five N95 masks will be provided to each doctor, nursing officer, technical staff, security guard and maintenance staff for 20 days at the AIIMS. "N95 masks to be disinfected by individual users and re-used at least four times each, whereby these will suffice for about 20 days" the circular issued by AIIMS read. Earlier on Saturday, AIIMS New Delhi administration had said that there is no shortage of Personnel Protective Equipment (PPE) for the healthcare workers at the institute. "AIIMS administration reiterates that there is no shortage of PPEs for health care workers (HCW) at the Institute" read the statement from Medial and Protocol Division, AIIMS, New Delhi. Personnel Protective Equipment acts as the first line of defence for the medical personnel treating COVID-19 positive patients.

AIIMS says doctors, paramedics, nurses treating COVID-19 patients will be given hydroxychloroquine tablets 

hydroxychloroquine-tablets

Hydroxychloroquine Tablets, News on Hydroxychloroquine Tablets, stories on Hydroxychloroquine Tablets, articles on Hydroxychloroquine Tablets, Hydroxychloroquine Tablets stories at Wion, Hydroxychloroquine Tablets news, Hydroxychloroquine Tablets latest news